Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of 16.73 billion. The enterprise value is 20.30 billion.
| Market Cap | 16.73B |
| Enterprise Value | 20.30B |
Important Dates
The last earnings date was Tuesday, August 18, 2026.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | May 22, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.25% |
| Owned by Institutions (%) | 20.67% |
| Float | 144.57M |
Valuation Ratios
The trailing PE ratio is 39.63 and the forward PE ratio is 18.53.
| PE Ratio | 39.63 |
| Forward PE | 18.53 |
| PS Ratio | 3.85 |
| PB Ratio | 8.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 17.47 |
| P/OCF Ratio | 14.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.68, with an EV/FCF ratio of 21.19.
| EV / Earnings | 48.08 |
| EV / Sales | 4.60 |
| EV / EBITDA | 14.68 |
| EV / EBIT | 17.05 |
| EV / FCF | 21.19 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.78.
| Current Ratio | 1.56 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.78 |
| Debt / EBITDA | 2.67 |
| Debt / FCF | 3.80 |
| Interest Coverage | 11.52 |
Financial Efficiency
Return on equity (ROE) is 18.53% and return on invested capital (ROIC) is 14.74%.
| Return on Equity (ROE) | 18.53% |
| Return on Assets (ROA) | 10.12% |
| Return on Invested Capital (ROIC) | 14.74% |
| Return on Capital Employed (ROCE) | 19.05% |
| Weighted Average Cost of Capital (WACC) | 6.34% |
| Revenue Per Employee | 252,499 |
| Profits Per Employee | 24,529 |
| Employee Count | 17,213 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.36 |
Taxes
In the past 12 months, Coloplast has paid 185.36 million in taxes.
| Income Tax | 185.36M |
| Effective Tax Rate | 30.51% |
Stock Price Statistics
The stock price has decreased by -23.24% in the last 52 weeks. The beta is 0.55, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -23.24% |
| 50-Day Moving Average | 6.53 |
| 200-Day Moving Average | 7.22 |
| Relative Strength Index (RSI) | 67.96 |
| Average Volume (20 Days) | 97,504 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of 4.35 billion and earned 422.22 million in profits. Earnings per share was 1.87.
| Revenue | 4.35B |
| Gross Profit | 2.92B |
| Operating Income | 1.17B |
| Pretax Income | 607.58M |
| Net Income | 422.22M |
| EBITDA | 1.32B |
| EBIT | 1.17B |
| Earnings Per Share (EPS) | 1.87 |
Balance Sheet
The company has 124.85 million in cash and 3.64 billion in debt, with a net cash position of -3.51 billion.
| Cash & Cash Equivalents | 124.85M |
| Total Debt | 3.64B |
| Net Cash | -3.51B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.04B |
| Book Value Per Share | 9.07 |
| Working Capital | 571.06M |
Cash Flow
In the last 12 months, operating cash flow was 1.17 billion and capital expenditures -214.55 million, giving a free cash flow of 958.13 million.
| Operating Cash Flow | 1.17B |
| Capital Expenditures | -214.55M |
| Depreciation & Amortization | 147.92M |
| Net Borrowing | -111.52M |
| Free Cash Flow | 958.13M |
| FCF Per Share | n/a |
Margins
Gross margin is 67.23%, with operating and profit margins of 26.98% and 9.71%.
| Gross Margin | 67.23% |
| Operating Margin | 26.98% |
| Pretax Margin | 13.98% |
| Profit Margin | 9.71% |
| EBITDA Margin | 30.32% |
| EBIT Margin | 26.98% |
| FCF Margin | 21.66% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 2.98%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 2.98% |
| Dividend Growth (YoY) | 11.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 187.59% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 3.06% |
| Earnings Yield | 2.52% |
| FCF Yield | 5.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Coloplast is 8.32, which is 14.60% higher than the current price. The consensus rating is "Hold".
| Price Target | 8.32 |
| Price Target Difference | 14.60% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.51% |
| EPS Growth Forecast (3Y) | 16.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Coloplast has an Altman Z-Score of 3.78 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.78 |
| Piotroski F-Score | 6 |